-
2
-
-
33750374233
-
EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
-
Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 1301-1311
-
-
Zhang, W.1
Doherty, M.2
Pascual, E.3
-
4
-
-
18144366916
-
Recent advances in the management of gout and hyperuricemia
-
Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005;17:319-24.
-
(2005)
Curr Opin Rheumatol
, vol.17
, pp. 319-324
-
-
Wortmann, R.L.1
-
5
-
-
33748608331
-
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
-
Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 1312-1324
-
-
Zhang, W.1
Doherty, M.2
Bardin, T.3
-
6
-
-
4043075471
-
Gout: On the brink of novel therapeutic options for an ancient disease
-
Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004;50:2400-14.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 2400-2414
-
-
Bieber, J.D.1
Terkeltaub, R.A.2
-
7
-
-
20844447189
-
Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: Another insight to allopurinol-related toxicity
-
Perez-Ruiz F, Hernando I, Villar I, Nolla JM. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity. J Clin Rheumatol 2005;11:129-33.
-
(2005)
J Clin Rheumatol
, vol.11
, pp. 129-133
-
-
Perez-Ruiz, F.1
Hernando, I.2
Villar, I.3
Nolla, J.M.4
-
8
-
-
33746717478
-
Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout
-
Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50.
-
(2006)
J Rheumatol
, vol.33
, pp. 1646-1650
-
-
Dalbeth, N.1
Kumar, S.2
Stamp, L.3
Gow, P.4
-
9
-
-
10344228746
-
Current management of gout in patients unresponsive or allergic to allopurinol
-
Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine 2004;71:481-5.
-
(2004)
Joint Bone Spine
, vol.71
, pp. 481-485
-
-
Bardin, T.1
-
11
-
-
0035147111
-
Efficacy and safety of desensitization to allopurinol following cutaneous reactions
-
Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001;44:231-8.
-
(2001)
Arthritis Rheum
, vol.44
, pp. 231-238
-
-
Fam, A.G.1
Dunne, S.M.2
Iazzetta, J.3
Paton, T.W.4
-
12
-
-
0036240985
-
Rasburicase: A potent uricolytic agent
-
Pui CH. Rasburicase: a potent uricolytic agent. Exp Opin Pharmacother 2002;3:433-42.
-
(2002)
Exp Opin Pharmacother
, vol.3
, pp. 433-442
-
-
Pui, C.H.1
-
13
-
-
11844278229
-
Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy- associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial
-
Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy- associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005;19:34-8.
-
(2005)
Leukemia
, vol.19
, pp. 34-38
-
-
Jeha, S.1
Kantarjian, H.2
Irwin, D.3
-
14
-
-
14044273556
-
Urate oxidase (rasburicase) for treatment of severe tophaceous gout
-
Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 2005;20:431-3.
-
(2005)
Nephrol Dial Transplant
, vol.20
, pp. 431-433
-
-
Vogt, B.1
-
15
-
-
33746463120
-
Rasburicase treatment in severe tophaceous gout: A novel therapeutic option
-
Moolenburgh JD, Reinders MK, Jansen TL. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol 2006;25:749-52.
-
(2006)
Clin Rheumatol
, vol.25
, pp. 749-752
-
-
Moolenburgh, J.D.1
Reinders, M.K.2
Jansen, T.L.3
-
16
-
-
33744963408
-
Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol
-
Richette P, Bardin T. Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol 2006;2:338-43.
-
(2006)
Nat Clin Pract Rheumatol
, vol.2
, pp. 338-343
-
-
Richette, P.1
Bardin, T.2
-
17
-
-
28844492990
-
Tophaceous gout: Quantitative evaluation by direct physical measurement
-
Schumacher HR Jr, Becker MA, Palo WA, Streit J, MacDonald PA, Joseph-Ridge N. Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol 2005;32:2368-72.
-
(2005)
J Rheumatol
, vol.32
, pp. 2368-2372
-
-
Schumacher Jr, H.R.1
Becker, M.A.2
Palo, W.A.3
Streit, J.4
MacDonald, P.A.5
Joseph-Ridge, N.6
-
18
-
-
0034827359
-
Relation between adverse events associated with allopurinol and renal function in patients with gout
-
Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3.
-
(2001)
Ann Rheum Dis
, vol.60
, pp. 981-983
-
-
Vazquez-Mellado, J.1
Morales, E.M.2
Pacheco-Tena, C.3
Burgos-Vargas, R.4
-
19
-
-
0037352829
-
Elitek-rasburicase: An effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002
-
Navolanic PM, Pui CH, Larson RA, et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia 2003;17:499-514.
-
(2003)
Leukemia
, vol.17
, pp. 499-514
-
-
Navolanic, P.M.1
Pui, C.H.2
Larson, R.A.3
-
20
-
-
33645739675
-
Rasburicase: A review of its use in the management of anticancer therapy-induced hyperuricaemia
-
Oldfield V, Perry CM. Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia. Drugs 2006;66:529-45.
-
(2006)
Drugs
, vol.66
, pp. 529-545
-
-
Oldfield, V.1
Perry, C.M.2
-
21
-
-
33947232486
-
Rasburicase (Elitek): A novel agent for tumor lysis syndrome
-
Ueng S. Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc Bayl Univ Med Cent 2005;18:275-9.
-
(2005)
Proc Bayl Univ Med Cent
, vol.18
, pp. 275-279
-
-
Ueng, S.1
-
22
-
-
0038102704
-
Rasburicase for the treatment and prevention of hyperuricemia
-
Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 2003;37:1047-54.
-
(2003)
Ann Pharmacother
, vol.37
, pp. 1047-1054
-
-
Yim, B.T.1
Sims-McCallum, R.P.2
Chong, P.H.3
-
23
-
-
27344455353
-
Hemolysis and methemoglobinemia secondary to rasburicase administration
-
Browning LA, Kruse JA. Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother 2005;39:1932-5.
-
(2005)
Ann Pharmacother
, vol.39
, pp. 1932-1935
-
-
Browning, L.A.1
Kruse, J.A.2
-
24
-
-
14944345365
-
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout
-
Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-23.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 916-923
-
-
Becker, M.A.1
Schumacher Jr, H.R.2
Wortmann, R.L.3
-
25
-
-
28944437578
-
Febuxostat compared with allopurinol in patients with hyperuricemia and gout
-
Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
-
(2005)
N Engl J Med
, vol.353
, pp. 2450-2461
-
-
Becker, M.A.1
Schumacher Jr, H.R.2
Wortmann, R.L.3
-
26
-
-
33947119693
-
Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout
-
Sundy JS, Ganson NJ, Kelly SJ, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007;56:1021-8.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 1021-1028
-
-
Sundy, J.S.1
Ganson, N.J.2
Kelly, S.J.3
|